NCT06517017 2025-11-28
UltraFrailMM
University of Utah
Phase 2 Recruiting
Clinical Trials
8 trialsNCT02547662 2023-10-30
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Mayo Clinic
Phase 2 Completed
NCT00821249 2020-10-19
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Pfizer
Phase 1/2 Completed
NCT01248923 2020-09-30
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Array BioPharma
Phase 1 Completed
NCT04008888 2019-07-05
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Unknown
NCT03591744 2018-12-19
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
City of Hope Medical Center
Phase 1 Withdrawn
NCT01553357 2012-03-14
Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia
IRCCS Centro di Riferimento Oncologico della Basilicata
Phase 2 Completed
NCT01328236 2011-09-22
Bortezomib
Clinical Service, China
Phase 2 Unknown